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Abstract  
Chronic kidney disease is recognized as a major health problem. 
Numbers of prevalent SRK patients will continue to rise, reflecting the 
growing elderly population and increasing numbers of patients with diabetes 
and hypertension. 
As numbers of SRK patients increase, primary care practitioners will be 
confronted with management of the complex medical problems unique to 
patients with chronic renal impairment. As well documented in the literature, 
the nephrologist rarely manages the medical needs of SRK patients until 
renal replacement therapy is required. The most frequent complications 
associated with SRK: anemia, hyperlipidemia, nutrition, osteodystrophy, and 
cardiovascular risk. 
Patients with SRK present several complex management issues to health care 
providers. The staging system introduced by the National Kidney Foundation 
is a significant accomplishment, which stratifies patients according to disease 
severity. In addition, the guidelines are an excellent tool for management of 
SRK and dialysis patients and recommend treatments according to disease 
stage. These interventions may reduce morbidity and mortality in these 
patients. With early identification and treatment of anemia, renal 
osteodystrophy, uremia, hyperlipidemia, and cardiovascular disease, primary 
care physicians and nephrologists together are making significant strides 
toward extending and improving the lives of patients with chronic renal 
disease. 
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INTRODUCTION 
 Renal chronic disease (RCD) is defined as kidney damage or 
decrease of the rate of glomerular filtration (GFR) below 60 ml / min per 
1.73 m2 in 3 months or more, regardless of the cause. Kidney Disease 
Quality Initiative (KDOQI) has classified RCD in five stages. (KJDOQI-
2012) 
 National Institute of Health and Clinical Excellence in the UK 
(NICE) in 2008 has modified this classification, dividing stage 3 of the RCD 
into 3A and 3B, respectively GFR 45-59 MI / mm for 1.73 m2 and 30-44 MI 
/ .2 mm for 1.73 m2. 
 Epidemiology of Renal Chronic Disease 
 The true incidence and prevalence of CRD within a community are 
difficult to ascertain quickly in moderated RCD because it is usually 
asymptomatic. However, various epidemiological studies are trying to clarify 
this issue and have made relatively similar observations suggesting a 
prevalence of RCD around 10%, albuminuria (mainly micro albuminuria)  
around 7%, and GFR below 60 ml / min per 1.73 m2  around 3%. 
 Examples of some studies based on representative population in the 
epidemiological study of RCD. 
Study State Project N  Result       
(%) MA 
Result      (%)  
RCD 
NHANES III USA CS/L 15.626 12 11 
PREVEND Netherland  CS/L 40.000 7  
NEOERICA United 
Kingdom 
CS/service 
based 
130.226  11(F),6(M) 
HUNT II Norway  CS 65.181 6 10 
EPIC-Norfolk United 
Kingdom 
CS 23.964 12  
MONICA 
Augsburg 
Germany CS 2.136 8  
AusDiab Australia CS 11.247 6 10 
Taiwan Taiwan CS/L 462.293  12 
Beijing China CS 13.925  13 
Takahata Japan CS 2.321 14  
Table 1. Representation of some population-based studies in the epidemiology of RCD 
(Jurgen Floege, Richard J. Johnson, John Feehally 2011) 
 
Epidemiology of last stage of the renal disease (ESRD) 
 Global epidemiology of ESRD is heterogeneous and influenced by 
several factors. As a result, the incidence and prevalence of ESRD vary 
greatly from country to country. 
 Disparities in ESRD incidence and spread within and between 
developed countries reflect the racial and ethnic differences and their impact 
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on the spread of diabetes and hypertension in the respective countries and 
communities. 
 Recently, different rates of progression of the CRD population, 
referral patterns, and pre-ESRD care quality have been associated with the 
heterogeneity of ESRD rates in different parts of the world. Inequalities in 
developing countries are likely to reflect the stability and access to renal 
replacement therapy (RRT) in the low and average economies.  
 The cost of treating patients with ESRD is significant and has an 
impact on the care provision, in this context, it is proposed that there is a 
clear and direct connection between the gross national product and the 
availability of RRT in most countries. (Scena FP 2000) During the next 
decade, the industrialized nations will struggle to meet the demands of ESRD 
expansion programs; in the United States, it is estimated that the annual costs 
for ESRD will reach more than US $ 52 by 2030.(USRD 2007) 
 In UK, renal services currently receive about 2% of the budget of the 
National Health Service, and it is set to grow with the increasing number of 
people requiring RRT globally.(Asell D, Feehally J, Feest-2006) 
Factors that influence the onset and progression of chronic renal disease 
Summary of risk factors associated with the onset and progression of 
the CRD 
Initiating factors Progression factors  
Systemic hypertension  Age (Being old) 
Diabetes mellitus  Gender (male) 
Cardiovascular diseases  Race/ Ethnicity  
Dyslipidemia Genetic predisposition  
Obesity/ Metabolic syndrome  Low management of blood pressure  
Hyperuricemia  Low management of glycemic  
Smoking  Proteinuria 
Low social and economic status  Cardiovascular disease  
Exposure to nefrotoxins: NSAIDs, 
analgesics, use of traditional herbs, 
exposure to heavy metals (like lead) 
Dyslipidemia                                     
Smoking                                            
Obesity/ Metabolic syndrome       
Hyperuricemia                                             
Low social and economic status                        
Alcohol consummation   Nefrotoxins   AIJS 
Radio-contrast materials   Medical herbs   
Acute kidney damage 
Table 2. Summary of risk factors associated with the onset and progression of the CRD. 
 
NSAIDs, non steroadal anti-inflammatory drugs; RCM, radiocontrast 
materials. 
 Known CRD susceptibility factors include genetic predisposition and 
family, race (African-Caribbean, Indo-Asian), maternal-fetal factors (low 
birth weight, malnutrition in uterus), age (elderly), and gender (male). 
Beyond CRD sensitivity, acceptance factors are likely to cause illness. 
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THE PURPOSE  
 This research aims to serve the medical, the patient and the 
community in general regarding: 
 • Coordination of appropriate services for patients identified with 
CRD 
 • Assessment and management of co-morbid conditions to decrease 
the loss of kidney function 
 • Assessment and management of risk factors to prevent or treat 
cardiovascular disease 
 • Evaluation and treatment of complications associated with reduced 
kidney function 
 • Preparation of patients for kidney failure and replacement therapy 
 • Coordination of services for kidney function by dialysis or 
transplantation in cases when they are indicated. 
 
MATERIALS AND METHODS 
 The study is typically descriptive, based on literature research related 
to clinical guidelines that are designed to assist clinicians by providing an 
analytical framework for the assessment and treatment of patients. They are 
not intended to replace the judgment of a clinician or to establish a protocol 
for all patients with a particular condition. 
 
THE RESULTS (RESEARCH COVERAGE) 
 Clinical evaluation and management of chronic kidney disease 
 Early detection of CRD with the introduction of a management plan 
algorithm disease can slow the rate of decline in kidney function and reduce 
cardiovascular risk.  Many patients with CRD are known by healthcare 
professionals because they are receiving treatment for hypertension, 
cardiovascular disease or diabetes. They can be identified because a high 
level of serum creatinine or urinary abnormality is detected in the next 
routine. 
• Evaluation of the patient with suspected chronic renal disease  
 The discovery of a calculated GFR (EGFR) of less than 60 ml / min 
in patients in whom renal function was unknown or normal, requires a 
history and examination with attention to blood pressure and urinalysis (for 
protein and blood) to assess whether the disease is acute or chronic. 
Proteinuria is an important diagnostic sign and warning, and its presence 
indicates a higher risk for progression of kidney disease and cardiovascular 
complications.(Asell D, Feehally J, Feest 2006) Blood pressure should be 
checked in all patients. Those with stage 3 to 5 stages of CRD should be 
evaluated for other complications such as dyslipidemia, anemia, and 
biochemical disorders that characterize bone mineral disorder. 
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• Clinical manifestations 
 With the exception of hypertension, CRD has few clinical 
manifestations during phases 1 and 2 (GFR> 60 MI / mm to 1.73 m2), the 
presence of proteinuria or hematouria is the basic indicator of kidney disease. 
Other complications (discussed in the following sections) tend to develop 
progressively as the GFR falls below 60 and especially below 30 ml / min 
per 1.73 m2 (ie, stages 4 and 5 CRD) 
a. Hypertension 
 About 50% to 75% of individuals with stage 3-5 CRD have 
hypertension. Control of blood pressure slows the rate of decline in kidney 
function and reduces cardiovascular complications. All classes of 
antihypertensive agents can be used in patients with CRD, although agents 
blocking the renin - angiotensin (RAS) can offer better renoprotection . 
Multidrug therapies are usually needed to achieve blood pressure control. 
Traditional lifestyle should be encouraged. In general, thiazides are 
recommended in patients with stage 1 to 3 CRD and the Loop of Henle 
diuretics in those with the most severe damage in the kidney. Available 
evidence aim a blood pressure below 130/80 mm Hg for CRD patients not 
receiving dialysis, but below 125/75 mm Hg for those with urinary protein 
excretion of more than 1g/24 hour.(KDOQI-2003) 
b. Dyslipidemia 
 CRD stage 3 patients often develop dyslipidemia with elevated 
plasma triglycerides and low high-density lipoprotein cholesterol. (KDOQI-
2003) 
 CRD patients in stage 3 who also have vascular disease can benefit 
from the therapy with statins, but until today there is no strong proof to 
suggest that CRD patients without disease of the blood vessels or those with 
more advanced stages of CRD can benefit from these drugs. Moreover, the 
risk of myopathy is increased from the use of fibrates and statins in CKID. 
Therefore fiber dosage should be reduced in patients with stage 3 and 4 of 
CRD and fibrates should be avoided in stage 5 of CRD. Statins should be 
initiated with low initial doses due to the accumulation of the drug. 
c. Anemia 
 Anemia is common in stage 3-5 of CRD and is caused by a relative 
erythropoietin deficiency, although reduced iron availability and chronic 
inflammation are common contributory factors. Anemia may contribute to 
cardiac dysfunction and left ventricular hypertrophy. Hemoglobin 
concentration is recommended at a level of 11 -13 g / dl. (Kalantar-Zadeh K 
2005) Partial correction of anemia does not accelerate the decline of renal 
function, but may require increases in antihypertensive therapy. 
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d. Mineral metabolism and the bone 
 Hyperphosphatemia together with the deficiency of 1,25- 
dihydroxyvitamin D3 contribute to secondary hyperparathyroidism. 
Prevention of secondary hyperparathyroidism requires dietary phosphate 
restrictions and administration in binders of phosphate.( Locatelli F, Aljama 
P, Barany P 2004) Many CRD patients with stage 3 and 4 are also deficient 
in 25 - hydroxyvitamin D3 (Levin A,Bakris GL, Molitch M 2005), and 
replacement by mouth with vitamin D3 can increase the levels of plasma 
derivative 1.25 - dihydroxy .(KDOQI-2003) 
e. Metabolic acidosis 
 Metabolic acidosis associated with CRD is caused by the failure of 
extraction of hydrogen ions and can be combined with bicarbonate loss. 
Severe metabolic acidosis (eg, serum bicarbonate <20 mrnol / l) associated 
with symptoms in a patient with stage 5 of the CRD is a sign to start dialysis. 
If dialysis is not immediately available, sodium bicarbonate orally at a dose 
up to 1.2 g four times a day may be considered. 
f. Malnutrition 
 Malnutrition is common among patients on dialysis, but also occurs 
in stages 4 and 5 and CRD is associated with an increased risk of death. 
(Kalantar-Zadeh K.2005) The causes are multifactorial and include anorexia, 
acidosis, insulin resistance, inflammation, oxidative stress and loss of urinary 
protein. Biochemical indicators include a decrease of albumin, transferrin 
and cholesterol in serum. Weight should be monitored in patients who 
progress to stages 4 and 5 of CRD. If patients do not respond to dietary 
meeting, initiation of dialysis should be considered. 
g. Psychological manifestations 
 Anxiety and depression are common in patients with severe CRD and 
they are due to loss of health and lifestyle changes. Management consists of 
education and counseling. Short-term antidepressant therapy can help, and 
some patients benefit from sedation at night, especially during hospital 
admissions. 
 
CONCLUSION 
• Since the number of patients with CRD increases, primary care 
physicians will be faced with complex and unique managing medical 
problems for patients with chronic renal impairment. CRD patients 
present complex management problems to health care providers. 
With early examination and treatment of anemia, renal 
osteodystrophy, uremia, hyperlipidemia, and cardiovascular disease, 
primary care physicians together with nephrologists can make 
significant steps towards improving the life and extending it to 
patients with chronic diseases renal. 
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• Although the management of patients with initial not progressive 
CRD is becoming the responsibility of primary care physicians, 
nephrologists should evaluate those individuals who are likely to 
progress ESRD and require renal replacement therapy. Criteria for 
referral are included in management algorithms. Such criteria are not 
absolute, but should provide a guide to the primary care physician as 
to which patients are likely to benefit from secondary care. 
• Over 20 million adults in the US have CRD, and 20 million others at 
increased risk. Education about CRD should be part of the 
management of people at risk of CRD. 
• People at risk should have regular measurements of creatinine, 
albumin in the urine and blood pressure. 
• Changes in lifestyle - exercise, smoking cessation, healthy food. 
• Pursuit of medications 
• Strict control of blood pressure and glycemic reduces the risk for 
CRD. 
• Early treatment of CRD with ACEI / ARB reduces the risk of kidney 
failure and CDK 
• Treatment of anemia improves QOL and is associated with reduced 
risk for CDK. 
• Healthy bones - calcium and security. 
• Nutrition - adequate protein and calories consumption, phosphorus 
and calcium management. 
• Avoid toxic renal therapies - NSAIDs, IV contrast, certain antibiotics, 
etc. 
• Fluid Management, prevention of infections 
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